Targeting CD117 with Astatine-211 to treat Acute Myeloid Leukemia and Myelodysplastic Syndrome
CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
This study is testing a new treatment that uses a special combination of antibodies and a radioactive substance to help patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) by targeting cancer cells more directly while protecting healthy ones.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10670383 on NIH RePORTER |
What this research studies
This research investigates the use of a targeted therapy that combines monoclonal antibodies with a radioactive substance called astatine-211 to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The approach focuses on delivering high doses of radiation directly to cancer cells while minimizing damage to surrounding healthy cells. By targeting the CD117 receptor, which is important for the growth and survival of blood cells, this therapy aims to improve treatment outcomes for patients. The study will explore the effectiveness and safety of this method in a clinical setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or myelodysplastic syndrome who have not responded well to standard treatments.
Not a fit: Patients with other types of blood cancers or those who are not eligible for targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and targeted treatment option for patients suffering from AML and MDS.
How similar studies have performed: Previous research has shown promise in using targeted radioimmunotherapy for blood cancers, but this specific approach using astatine-211 is relatively novel.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Walter, Roland Bruno — Fred Hutchinson Cancer Center
- Study coordinator: Walter, Roland Bruno
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.